Zevra Therapeutics, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Zevra Therapeutics, Inc. (ZVRA) reported Adjustments to Additional Paid in Capital, Warrant Issued of $11.16 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-05
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-03-31 was $11.16M, a 463.92% increase year-over-year.
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was $13.12M.
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-03-31 was $1.98M.
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-06-30 was $17.09M.
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $16.65M.
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $4.50M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2026-03-31 | $11.16M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $16.65M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $13.12M 10-Q · filed 2025-11-05 | |
| 2025-03-31 | $1.98M 10-Q · filed 2026-05-06 | |
| 2023-12-31 | $4.50M 10-K · filed 2025-03-12 | |
| 2021-06-30 | $17.09M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |